Loading patent…
AssigneeMedipost Co., Ltd.
InventorsJong Wook CHANG, Dal Soo KIM, Yoon-Sun YANG, Won Il OH
Estimating the term…
Provided is a gene therapy composition for transferring one of a therapeutical gene, a maker gene, or a mixture thereof to a cell that expresses interleukin-8(IL-8) or GRO-α and induces tropism of mesenchymal stem cells isolated from umbilical cord blood and/or the mesenchymal stem cells expanded from said mesenchymal stem cells (UCB-MSCs), wherein the cell-treating composition includes UCB-MSCs. Provided is a composition for treating disease related to a cell expressing IL-8 or GRO-α, that is, a brain tumor in gene therapy, by using UCB-MSCs. Provided is a composition or kit for diagnosing brain tumors, preventing brain tumors, treating brain tumors, or monitoring brain tumor treatment progression by using UCB-MSCs.
A method of preventing or treating a tumor comprising administering to a subject an effective dose of a composition comprising mesenchymal stem cells derived from umbilical cord blood (UCB-MSC).
A kit for identifying the location and the size of a brain tumor, comprising UCB-MSC, said UCB-MSC being labeled with a detectable marker.
A method of identifying the location and the size of a brain tumor of a subject, wherein the method comprises:
A method of monitoring a progression of a tumor treatment in a subject who is received the brain tumor treatment, wherein the method comprises:
A method for delivering a therapeutic gene to a site of a subject, the site comprising cells expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cells, wherein the method comprises the step of administering to the subject an effective dose of the UCB-MSC.
A kit for identifying the location and the size of a site of a subject, the site comprising cells expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cells, wherein the kit comprises UCB-MSC, the UCB-MSC are labeled with a detectable marker.
A method of identifying the location and the size of a site of a subject, the site comprising cells expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cells, wherein the method comprises:
A method of monitoring treatment progression of a disease occurred in a site of a subject, the site comprising cells expressing at least one selected from groups consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC, wherein the method comprises:
A method of delivering an anti-tumor agent to a site of a tumor in a subject, which comprises administering mesenchymal stem cells together with the anti-tumor agent to the site, wherein the mesenchymal stem cells (MSCs) are umbilical cord blood-derived MSCs (“UCB-MSC”).
Dependencies are inferred from the claim text.